东阳光药IPO:收入依赖单一产品,近年来利润大幅波动

面包财经
Jun 23

近日,东阳光药更新了港股上市申请书,中金公司担任独家保荐人。东阳光药成立于2003年,是综合性制药企业,公司聚焦感染、慢病和肿瘤治疗领域。2022-2024年,公司抗感染药物收入占总营收的85%、90%、69.6%,其中公司核心产品磷酸奥司他韦(用于治疗流行性感冒)销售额在各年分别占年度收入的81.2%、86.9%、64.2%。对于2024年磷酸奥司他韦销售额下降原因,公司表示主要系2024年中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10